As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Collegium Pharmaceutical Inc. The largest reported stake is Millennium Management LLC's, at 7.4%. 19 filings are on record since August 7, 2025 (Schedule 13G/A, October 8, 2026).
Sell to companies like Collegium Pharmaceutical Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Vanguard Capital Management · Sole voting: 245,798 · Shared voting: 0 · Sole dispositive: 1,621,026 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-30
- · Reporting person: Principal Global Investors · Sole voting: 0 · Shared voting: 1,514,310 · Sole dispositive: 0 · Shared dispositive: 1,514,310 · SCHEDULE 13G/A, 2026-10-29
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 1,897,471 · Sole dispositive: 0 · Shared dispositive: 1,897,471 · SCHEDULE 13G/A, 2026-10-08
- · Holder: Millennium Management LLC · Percent: 5.6% · SCHEDULE 13G
- · Reporting person: Fuller & Thaler Asset Management, Inc. · Sole voting: 1,632,781 · Shared voting: 0 · Sole dispositive: 1,632,781 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
Collegium Pharmaceutical Inc has 19 Schedule 13D or 13G filings on record since 2025-08-07. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Millennium Management LLC | 7.4% | 2,400,985 | SCHEDULE 13G/A, 2026-10-08 | 2026-09-30 |
| Janus Henderson Group Plc | 5.8% | 1,825,651 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Fuller & Thaler Asset Management, Inc. | 5.03% | 1,632,781 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Invesco Ltd. | 5% | 1,591,909 | SCHEDULE 13G, 2026-05-08 | 2026-03-31 |
| Vanguard Capital Management | 4.97% | 1,621,026 | SCHEDULE 13G/A, 2026-10-30 | 2026-09-30 |
| Rubric Capital Management LP | 4.73% | 1,496,436 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Principal Global Investors | 4.7% | 1,514,310 | SCHEDULE 13G/A, 2026-10-29 | 2026-09-30 |
| Renaissance Technologies LLC | 4.53% | 1,469,449 | SCHEDULE 13G/A, 2026-05-14 | 2026-01-08 |
| Eventide Asset Management, LLC | 4.5% | 1,424,282 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Collegium Pharmaceutical Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Collegium Pharmaceutical Inc and the records around it.
Collegium Pharmaceutical Inc elsewhere on the record
- Leadership changes May 2026
- Who owns it
Companies that share a holder
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Immix Biopharma, Inc. (Aug 2026), Ovid Therapeutics Inc. (Aug 2026), Beta Bionics, Inc. (May 2026)
- PRINCIPAL GLOBAL INVESTORS also filed stake reports on 19 other companies: Brookfield Infrastructure Partners L.P. (Oct 2026), Hyatt Hotels Corp (Oct 2026), National Healthcare Properties, Inc. (Oct 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
Watch Collegium Pharmaceutical Inc
Get an email when Collegium Pharmaceutical Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Collegium Pharmaceutical Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Collegium Pharmaceutical Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Collegium Pharmaceutical Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Integrated Core Strategies (US) LLC | 0 | 1,897,471 | 0 | 1,897,471 | SCHEDULE 13G/A, 2026-10-08 |
| Millennium Management LLC | 0 | 2,400,985 | 0 | 2,400,985 | SCHEDULE 13G/A, 2026-10-08 |
| Millennium Group Management LLC | 0 | 2,400,985 | 0 | 2,400,985 | SCHEDULE 13G/A, 2026-10-08 |
| Israel A. Englander | 0 | 2,400,985 | 0 | 2,400,985 | SCHEDULE 13G/A, 2026-10-08 |
| Fuller & Thaler Asset Management, Inc. | 1,632,781 | 0 | 1,632,781 | 0 | SCHEDULE 13G, 2026-08-14 |
| Vanguard Capital Management | 245,798 | 0 | 1,621,026 | 0 | SCHEDULE 13G/A, 2026-10-30 |
| Principal Global Investors | 0 | 1,514,310 | 0 | 1,514,310 | SCHEDULE 13G/A, 2026-10-29 |
The latest filing identifies Collegium Pharmaceutical Inc by CUSIP 19459J104 and gives its principal executive office as 100 Technology Center Dr, Suite 300, Stoughton, MA 02072 (SCHEDULE 13G/A, 2026-10-30).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-07 | Invesco Ltd. | 4.9% | SCHEDULE 13G/A |
| 2025-08-11 | Principal Global Investors | 4.6% | SCHEDULE 13G/A |
| 2025-08-13 | Renaissance Technologies LLC | 4.82% | SCHEDULE 13G/A |
| 2025-11-13 | Renaissance Technologies LLC | 5.06% | SCHEDULE 13G |
| 2026-02-13 | Rubric Capital Management LP | 4.73% | SCHEDULE 13G/A |
| 2026-02-13 | Eventide Asset Management, LLC | 5.9% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-08 | Invesco Ltd. | 5% | SCHEDULE 13G |
| 2026-05-12 | Integrated Core Strategies (US) LLC | 4.7% | SCHEDULE 13G |
| 2026-05-14 | Renaissance Technologies LLC | 4.53% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 5.8% | SCHEDULE 13G |
| 2026-05-15 | Eventide Asset Management, LLC | 4.5% | SCHEDULE 13G/A |
| 2026-07-31 | Vanguard Capital Management | 5.01% | SCHEDULE 13G |
| 2026-08-05 | Principal Global Investors | 5% | SCHEDULE 13G |
| 2026-08-14 | Fuller & Thaler Asset Management, Inc. | 5.03% | SCHEDULE 13G |
| 2026-08-24 | Millennium Management LLC | 5.6% | SCHEDULE 13G |
| 2026-10-08 | Millennium Management LLC | 7.4% | SCHEDULE 13G/A |
| 2026-10-29 | Principal Global Investors | 4.7% | SCHEDULE 13G/A |
| 2026-10-30 | Vanguard Capital Management | 4.97% | SCHEDULE 13G/A |
Questions about who owns Collegium Pharmaceutical Inc
Who owns Collegium Pharmaceutical Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Collegium Pharmaceutical Inc: Millennium Management LLC (7.4%, Schedule 13G/A, filed 2026-10-08), Janus Henderson Group Plc (5.8%, Schedule 13G, filed 2026-05-15), Fuller & Thaler Asset Management, Inc. (5.03%, Schedule 13G, filed 2026-08-14) and Invesco Ltd. (5%, Schedule 13G, filed 2026-05-08).
Who are the largest shareholders of Collegium Pharmaceutical Inc?
By the share each holder's latest filing reports, the largest holders of Collegium Pharmaceutical Inc on this page are Millennium Management LLC (7.4%), Janus Henderson Group Plc (5.8%) and Fuller & Thaler Asset Management, Inc. (5.03%).
When did Millennium Management LLC buy into Collegium Pharmaceutical Inc?
The filings give report dates, not purchase dates. The earliest filing from Millennium Management LLC on this page is the Schedule 13G, filed 2026-08-24, reporting 5.6%; its latest, Schedule 13G/A filed 2026-10-08, reports 7.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 19 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Collegium Pharmaceutical Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 12, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 7, 2026 | Leadership change: John Fallon departs, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Collegium Pharmaceutical Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.